First, because ANA testing is typically ordered for patients with clinical suspicion of autoimmune disease, the observed ANA positivity rate (35.3%) likely overestimates the true prevalence in the general population, and the findings should not be extrapolated beyond the hospital setting. Here, BTG3 is linked to autoimmune disease.